“Skin Clearance, Duration of Treatment-Free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-Week Phase 3 Trial in Adults and Children Down to 2 Years of Age With Atopic Dermatitis”. 2025. SKIN The Journal of Cutaneous Medicine 9 (2): s553. https://doi.org/10.25251/skin.10.supp.553.